Dexmedetomidine as an Adjuvant to Analgesic Strategy During Vaso-Occlusive Episodes in Adolescents with Sickle-Cell Disease.

Authors

Kathy A Sheehy
Julia C. Finkel, George Washington UniversityFollow
Deepika S. Darbari, George Washington UniversityFollow
Michael F. Guerrera, George Washington University
Zenaide M.N. Quezado, George Washington UniversityFollow

Document Type

Journal Article

Publication Date

7-23-2015

Journal

Pain Practice

Volume

15

Issue

8

Inclusive Pages

E90-7

DOI

10.1111/papr.12336

Keywords

Analgesics, Non-Narcotic--administration & dosage; Anemia, Sickle Cell--complications; Dexmedetomidine--administration & dosage; Pain--drug therapy; Pain Management--methods

APA Citation

Sheehy, K., Finkel, J., Darbari, D., Guerrera, M., & Quezado, Z. (2015). (463) Dexmedetomidine as an adjuvant to analgesic strategy during vaso-occlusive episodes in adolescents with sickle cell disease. Journal of Pain, 15(8), E90-E97. DOI: 10.1111/papr.12336

Peer Reviewed

1